Albert Labs International Corp is the first psychedelic company leveraging Real World Evidence Studies to enhance patient care by accelerating access to psychedelic therapy in a hospital setting for niche indications with urgent and high unmet needs. Through a collaboration with leading academic institutions, hospital networks and existing reimbursement mechanisms; Albert Labs empowers scientists, researchers, and medical professionals to accelerate safe patient treatment whilst collecting data to protect and improve its psilocybin-based medicines. Starting with cancer-related anxiety, depression and existential crisis, Albert Labs will bring psilocybin-assisted therapy to the UK and Europe before expanding globally.